Wellbeing Subsidiary KGK Science Applies for a Controlled Substances Dealers License and Receives Approval to Proceed with Buildout

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Sciences Inc. (“KGK” or the “Subsidiary”), has applied for a Controlled Substance Dealers License (“License”) from Health Canada.

The License would allow KGK to possess, import, sell and study several controlled substances including psilocybin, LSD, DMT, ketamine and MDMA. The company has received approval to proceed with the buildout of a level 5 security system at its state-of-the-art research facility in London Ontario. Following an inspection this spring, it is expected that KGK will receive the license which will permit the company to import and sell substances for medical and research purposes.

“Although still in its infancy. psychedelics have shown to be highly effective in treating several mental health conditions,” stated Najla Guthrie, CEO of Wellbeing and KGK. “Pursuing this License will enable us to process, formulate and perform the scientific tests required for our clients to move these promising treatments to market in a timely manner once the industry matures, ultimately staying at the forefront of drug development and regulations. This is yet another step towards our goal to maintain our position as a leader in this field and enable our clients to not only create safe and effective alternative treatments but leverage our Wellbeing North American clinical network to meet the growing patient demand, ultimately creating additional shareholder value.”

Under the Dealer’s License, KGK can possess up to 1,000 grams of psilocybin, LSD, DMT, ketamine and MDMA at any time and can transfer the extracted material to other companies who hold a valid Dealer’s License. Once approved, the company will be permitted to process and formulate a variety of psychedelic compounds, progressively used and sought-after by patients and healthcare practitioners to combat a variety of physical and mental illnesses.

ABOUT KGK SCIENCE

Subsidiary of Wellbeing Digital Sciences, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products. Founded in 1997, the business has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies to move products into global markets. KGK’s other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services and consulting services. Furthermore, the company has produced over 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in its database and collected 10 million data points. For additional information, please visit kgkscience.com.

ABOUT WELLBEING DIGITAL SCIENCES

Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development. For additional information, please visit wellbeingdigital.co.

On behalf of:
Najla Guthrie
Chief Executive Officer
WELLBEING DIGITAL SCIENCES

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

‍